Daiichi Sankyo, Merck collaborate to develop and commercialize three Daiichi Sankyo DXd ADCs
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
Eni will guarantee Dompé researchers access to its laboratories, support from the company's specialized staff, and use of its HPC5 supercomputer
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Increased capability to produce medicines for challenging diseases including cancer
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Subscribe To Our Newsletter & Stay Updated